Skip to content

Study · Animal study (in vivo) · mouse · 2015

6 results

Mitochondria-Targeted Peptide Reverses Mitochondrial Dysfunction and Cognitive Deficits in Sepsis-Associated Encephalopathy.

Wu J, Zhang M, Hao S, Jia M, Ji M, Qiu L, Sun X, Yang J, Li K

Molecular neurobiology7 Oct 2014Cited by 89 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In mice with sepsis-associated encephalopathy, SS‑31 protected the integrity of hippocampal mitochondria.

    In plain wordsIn mice with sepsis-related brain injury, SS‑31 protected the structure of mitochondria in the hippocampus.

    Outcome
    IncreaseMitochondrial integrity in hippocampus
    Study

    mousen: not reported in source

    Cecal ligation and puncture (CLP) sepsis-associated encephalopathy model
    Comparator
    CLP group
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · immediately after operation and once daily for six consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    administration of peptide SS-31 protected the integrity of mitochondria
    2 context sentences
    Summary · context
    C57BL/6 male mice were randomly divided into sham, sham + SS-31, cecal ligation and puncture (CLP), and CLP + SS-31 groups.
    Summary · context
    Peptide SS-31 (5 mg/kg) was intraperitoneally administrated immediately after operation and afterwards once daily for six consecutive days.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice with sepsis-associated encephalopathy, SS‑31 reversed hippocampal mitochondrial dysfunction.

    In plain wordsIn mice with sepsis-related brain injury, SS‑31 reversed mitochondrial problems in the hippocampus.

    Outcome
    DecreaseMitochondrial dysfunction in hippocampus
    Study

    mousen: not reported in source

    Cecal ligation and puncture (CLP) sepsis-associated encephalopathy model
    Comparator
    CLP group
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · immediately after operation and once daily for six consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    reversed the mitochondrial dysfunction
    2 context sentences
    Summary · context
    C57BL/6 male mice were randomly divided into sham, sham + SS-31, cecal ligation and puncture (CLP), and CLP + SS-31 groups.
    Summary · context
    Peptide SS-31 (5 mg/kg) was intraperitoneally administrated immediately after operation and afterwards once daily for six consecutive days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with sepsis-associated encephalopathy, SS‑31 inhibited apoptosis resulting from cytochrome c release.

    In plain wordsIn mice with sepsis-related brain injury, SS‑31 reduced brain cell death.

    Outcome
    DecreaseNeuronal apoptosis (cytochrome c release)
    Study

    mousen: not reported in source

    Cecal ligation and puncture (CLP) sepsis-associated encephalopathy model
    Comparator
    CLP group
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · immediately after operation and once daily for six consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    inhibited the apoptosis resulting from the release of cytochrome c
    2 context sentences
    Summary · context
    C57BL/6 male mice were randomly divided into sham, sham + SS-31, cecal ligation and puncture (CLP), and CLP + SS-31 groups.
    Summary · context
    Peptide SS-31 (5 mg/kg) was intraperitoneally administrated immediately after operation and afterwards once daily for six consecutive days.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with sepsis-associated encephalopathy, SS‑31 diminished the inflammatory response.

    In plain wordsIn mice with sepsis-related brain injury, SS‑31 reduced inflammation.

    Outcome
    DecreaseHippocampal inflammation
    Study

    mousen: not reported in source

    Cecal ligation and puncture (CLP) sepsis-associated encephalopathy model
    Comparator
    CLP group
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · immediately after operation and once daily for six consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    diminished the response of inflammation, and ultimately reversed the behavior deficits in the SAE mice.
    2 context sentences
    Summary · context
    C57BL/6 male mice were randomly divided into sham, sham + SS-31, cecal ligation and puncture (CLP), and CLP + SS-31 groups.
    Summary · context
    Peptide SS-31 (5 mg/kg) was intraperitoneally administrated immediately after operation and afterwards once daily for six consecutive days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with sepsis-associated encephalopathy, SS‑31 reversed the behavior deficits and ameliorated cognitive deficits.

    In plain wordsIn mice with sepsis-related brain injury, SS‑31 reversed thinking and behavior problems.

    Outcome
    IncreaseCognitive and behavior deficits
    Study

    mousen: not reported in source

    Cecal ligation and puncture (CLP) sepsis-associated encephalopathy model
    Comparator
    CLP group
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · immediately after operation and once daily for six consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    ultimately reversed the behavior deficits in the SAE mice.
    3 context sentences
    Summary · context
    In conclusion, our data demonstrate that daily treatment with mitochondria-targeted peptide SS-31 reduces mortality rate and ameliorates cognitive deficits, which is possibly through a mechanism of reversing mitochondrial dysfunction and partial inhibition of neuronal apoptosis and inflammation in t…
    Summary · context
    C57BL/6 male mice were randomly divided into sham, sham + SS-31, cecal ligation and puncture (CLP), and CLP + SS-31 groups.
    Summary · context
    Peptide SS-31 (5 mg/kg) was intraperitoneally administrated immediately after operation and afterwards once daily for six consecutive days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with sepsis-associated encephalopathy, daily SS‑31 reduced the mortality rate.

    In plain wordsIn mice with sepsis-related brain injury, daily SS‑31 lowered the death rate.

    Outcome
    DecreaseMortality rate
    Study

    mousen: not reported in source

    Cecal ligation and puncture (CLP) sepsis-associated encephalopathy model
    Comparator
    CLP group
    Outcome group
    Mortality · Whole body
    Studied dose
    5 mg/kg · intraperitoneal · immediately after operation and once daily for six consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    In conclusion, our data demonstrate that daily treatment with mitochondria-targeted peptide SS-31 reduces mortality rate and ameliorates cognitive deficits, which is possibly through a mechanism of reversing mitochondrial dysfunction and partial inhibition of neuronal apoptosis and inflammation in t…
    3 context sentences
    Summary · context
    The results showed that CLP resulted in high mortality rate and cognitive deficits, representative characteristics of SAE.
    Summary · context
    C57BL/6 male mice were randomly divided into sham, sham + SS-31, cecal ligation and puncture (CLP), and CLP + SS-31 groups.
    Summary · context
    Peptide SS-31 (5 mg/kg) was intraperitoneally administrated immediately after operation and afterwards once daily for six consecutive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.